| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEB4 |
| Uniprot No | O15481 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 活性数据 | MPRGQKSKLR AREKRQRTRG QTQDLKVGQP TAAEKEESPS SSSSVLRDTA SSSLAFGIPQ EPQREPPTTS AAAAMSCTGS DKGDESQDEE NASSSQASTS TERSLKDSLT RKTKMLVQFL LYKYKMKEPT TKAEMLKIIS KKYKEHFPEI FRKVSQRTEL VFGLALKEVN PTTHSYILVS MLGPNDGNQS SAWTLPRNGL LMPLLSVIFL NGNCAREEEI WEFLNMLGIY DGKRHLIFGE PRKLITQDLV QEKYLEYQQV PNSDPPRYQF LWGPRAHAET SKMKVLEFLA KVNDTTPNNF PLLYEEALRD EEERAGARPR VAARRGTTAM TSAYSRATSS SSSQPM |
| 分子量 | 38.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MAGEB4蛋白的3篇参考文献，基于公开研究整理：
---
1. **文献名称**: "MAGEB4 expression and antitumor immunity in melanoma"
**作者**: Wang Y. et al.
**摘要**: 本研究探讨了MAGEB4在黑色素瘤中的表达及其作为肿瘤抗原的潜在作用。通过重组人MAGEB4蛋白刺激T细胞实验，证实其能诱导特异性免疫反应，提示其在免疫治疗中的应用前景。
---
2. **文献名称**: "Recombinant expression and functional analysis of MAGEB4 in cancer cell lines"
**作者**: Tanaka R. et al.
**摘要**: 报道了利用大肠杆菌系统表达重组人MAGEB4蛋白，通过亲和层析纯化并验证其稳定性。实验显示该蛋白可与HLA-I类分子结合，支持其在肿瘤靶向治疗中的潜在用途。
---
3. **文献名称**: "Structural insights into the MAGEB4 protein and its interaction with RING ligase"
**作者**: Müller P. et al.
**摘要**: 采用X射线晶体学解析重组MAGEB4蛋白的结构，发现其C端结构域与E3泛素连接酶的相互作用界面。研究为理解MAGE家族蛋白调控泛素化通路的机制提供了依据。
---
注：以上文献信息为示例性内容，若需真实文献，建议通过PubMed或Web of Science以关键词"recombinant MAGEB4" "MAGEB4 cancer"等查询近期论文。
The melanoma-associated antigen (MAGE) family comprises proteins initially identified for their restricted expression in tumors and germline cells. MAGEB4. a member of the MAGE-B subfamily, is encoded by the *MAGEB4* gene located on the X chromosome. This subfamily, part of the broader MAGE-I group, shares a conserved MAGE homology domain involved in protein-protein interactions and regulatory functions. MAGEB4 is classified as a cancer-testis antigen (CTA) due to its predominant expression in normal testicular tissues and ectopic activation in various malignancies, including melanoma, lung, and breast cancers. Its tumor-specific expression and immunogenicity make it a potential target for immunotherapy.
Structurally, recombinant human MAGEB4 protein retains the characteristic 314-amino acid sequence with conserved motifs critical for binding E3 ubiquitin ligases, suggesting roles in ubiquitination pathways and tumorigenesis. In cancer, MAGEB4 overexpression correlates with immune evasion, possibly by modulating apoptosis or immune checkpoint signaling. Recombinant MAGEB4 is produced via prokaryotic or eukaryotic expression systems, enabling studies on its biological roles, antibody development, and vaccine design. Despite progress, functional mechanisms remain unclear, necessitating further research into its interaction networks and therapeutic applications. As a recombinant protein, it serves as a reagent for diagnostics, mechanistic studies, and preclinical validation of CTA-targeted therapies.
×
